Immunome (IMNM) Stock Movement and Contextual Market Insights

During the 24‑hour trading window that concluded at 08:49 PM Central Europe on Wednesday, October 21, 2026, the shares of Immunome, Inc. (ticker IMNM) exhibited a modest gain of 6.86 %. At the close, the stock was priced at approximately USD 18.04 on the Nasdaq exchange, with a total outstanding supply of 113.3 million shares. The company’s market capitalisation, calculated at this price point, stands at USD 1.9 billion. In the previous 24‑hour period, roughly USD 36.4 million worth of Immunome stock changed hands.

Technical Snapshot

  • Simple Moving Average (200‑day): USD 22.57
  • 52‑Week High: USD 30.06 (reached on 08/19/2026)
  • 52‑Week Low: USD 14.64 (reached on 11/07/2025)

The recent upward movement comes after a substantial decline of -28.52 % in the month‑end, signalling a possible rebound as the company’s share price approaches the 200‑day moving average.

Comparative Performance of Peer Stocks

Calix Inc. (CALX)

  • 24‑hour change: +1.23 %
  • Current price: USD 36.64
  • Market cap: USD 2.3 billion
  • P/E ratio: 48.76

Calix has recently expanded its managed‑service portfolio, unveiling SmartMDU capabilities on its Calix One platform and a trio of GigaPro managed switches. These product enhancements aim to deepen market penetration and streamline deployment for service providers.

Lindblad Expeditions Holdings, Inc. (LIND)

  • 24‑hour change: +3.29 %
  • Current price: USD 36.36
  • Market cap: USD 2.3 billion

Sven‑Olof Lindblad, a key director and major shareholder, executed Rule 10b‑5 trades, selling tens of thousands of shares in two separate transactions. Despite these sales, his ownership stake remains above ten percent, preserving significant influence over corporate governance.

DXC Technology Co. (DXC)

  • 24‑hour change: +2.59 %
  • Current price: USD 15.21
  • Market cap: USD 2.3 billion
  • P/E ratio: 20.18

DXC is reportedly pursuing the sale of its insurance software division to Eldridge Industries for approximately USD 2.4 billion. Concurrently, the company is actively repurchasing shares through a daily on‑market buy‑back program, signalling confidence in its core technology services.

Netlist Inc. (NLST)

  • 24‑hour change: -2.88 %
  • Current price: USD 6.20
  • Market cap: USD 2.3 billion
  • P/E ratio: 2,266.92

Netlist’s valuation remains highly stretched, reflecting the market’s caution regarding its earnings prospects.

UFP (UFPT)

  • 24‑hour change: -0.65 %
  • Current price: USD 290.17
  • Market cap: USD 2.3 billion
  • P/E ratio: 31.54

UFP maintains a modest decline, with its valuation metrics aligning more closely with industry averages.

About Immunome, Inc.

Immunome, Inc. is a biotechnology firm headquartered in Exton, Pennsylvania. The company focuses on the development and commercialization of novel therapeutic antibodies and medicines aimed at treating a variety of diseases. Immunome’s services are directed primarily at patients within Pennsylvania. Additional information about the company’s research, product pipeline, and corporate governance can be found on its website at www.immunome.com .

This article provides a concise yet comprehensive overview of Immunome’s recent trading performance, situating it within the broader context of peer company movements and market dynamics.